Revvity, Inc. (RVTY) AI Stock Analysis

Revvity, Inc. is a global provider of advanced health sciences solutions, technologies, and services operating through Life Sciences and Diagnostics segments. In Life Sciences, the company delivers instruments, reagents, informatics solutions, and software designed to improve scientific research and clinical lab workflows, backed by detection and imaging technologies. In Diagnostics, Revvity develops instruments, reagents, assay platforms, and software for early disease detection, including genetic disorders such as Down syndrome and muscular dystrophy, as well as infectious diseases. Its diagnostic technologies also support genomic workflows, utilizing G protein-coupled receptor advances and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery.

Revenue fell from $3.83B in FY2021 to $2.75B in FY2023, before rebounding to $2.76B in FY2024 and $2.86B in FY2025, yielding a 5-year revenue CAGR of -5.5%. Gross margin stood at 53.1% in FY2025, up from 48.0% in FY2024, while operating margin was 12.5%. Net income reached $241.7M in FY2025, recovering from -$118.4M in FY2023. Over the trailing twelve months, revenue was $2.91B with an operating margin of 17.1% and a profit margin of 8.2%. In the latest quarter ended June 30, 2026, quarterly revenue grew 1.3% year-over-year, while quarterly earnings grew 1.2%.

As of June 30, 2026, Revvity held $1.02B in cash and short-term investments alongside total debt of $3.34B, resulting in net debt of $2.32B. Shareholders' equity was $7.23B, with total assets of $12.05B, a debt-to-equity ratio of 0.46, and a current ratio of 1.80. In FY2025, operating cash flow reached $581.8M and free cash flow was $508.3M. Cash allocation in FY2025 included $73.5M in capital expenditures, $820.8M spent on share buybacks, and $32.8M paid in dividends.

Revvity carries a market cap of $17.03B and an enterprise value of $18.18B. Its trailing P/E of 73.0x and forward P/E of 24.2x compare to medians of 27.2x and 16.5x for its S&P 500 Healthcare peers. The company's EV/EBITDA is 23.5x versus the peer median of 15.0x, and its price-to-sales multiple is 5.8x compared to the peer median of 3.4x. Over the past year, the stock returned 62.8%, outperforming the S&P 500 (SPY) return of 16.8%, though its 5-year return of -9.0% lagged the index's 83.0% gain.

Revvity pays an annual forward dividend of $0.28 per share, yielding 0.18% with a payout ratio of 5.2%. Dividends are distributed quarterly, and the company has maintained 44 consecutive years of dividend payments. Its 5-year annualized dividend growth rate is 0.0%, and the last ex-dividend date was October 23, 2026.

Wall Street coverage consists of 6 Strong Buy, 11 Hold, and 1 Sell ratings. The mean price target is $147.53, which sits 3.3% below the last close of $152.64. For the current fiscal year ending December 31, 2026, analysts estimate EPS of $5.35 on revenue of $2.85B. For the next fiscal year, 17 analysts project EPS of $5.89 and revenue of $3.01B. Revvity beat EPS estimates in all 4 of the last 4 quarters, with its next earnings report scheduled for November 3, 2026.

This page is an AI-written research summary of Revvity, Inc. (RVTY). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: RVTY income statement, RVTY balance sheet, RVTY key metrics, RVTY analyst forecast, RVTY chart. See the RVTY stock overview for the latest quote and news.